102 results about "Immuno histochemistry" patented technology

Presented herein are systems, methods, and non-transient computer readable media for determining predicted response scores of subjects. A computing system may identify a first feature set for a first subject to be administered with immunotherapy to address a condition. The first feature set may include one or more of: (i) a first radiological feature identified in a tomogram of a section associated with the condition in the first subject, (ii) a first immunohistochemistry (IHC) feature derived from an image of a sample associated with the first subject, and (iii) a first genomic feature obtained from gene sequencing of the first subject for genes associated with the condition. The computing system may apply the first feature set to a model. The computing system may determine, from applying the first feature set to the model, a predicted score identifying a response to the immunotherapy to be administered to the first subject.

The utility model relates to a staining kit, in particular to an immunohistochemical staining kit. The kit comprises a storage box, a clamping plate is arranged in the storage box, a plurality of clamping grooves are evenly formed in the clamping plate, a kit body is arranged in the clamping grooves, a plurality of placing grooves are evenly formed in the kit body around the circle center, reagent bags are arranged in the placing grooves, and different reagents are stored in the reagent bags; a sliding groove is formed in the inner wall of the top end of the kit close to the placing groove, and a cutting assembly is slidably connected into the sliding groove and used for cutting the reagent capsule. According to the kit storage box, a combined structure of the clamping grooves and the kits is designed, and the kits are placed in the clamping grooves, so that the kits are orderly arranged in the storage box and are convenient to manage and take, the efficiency of an experiment preparation stage is favorably improved, and disorder and loss of the kits are reduced; the reagent bag body can be stably placed in the placing groove, stability and safety of the reagent in the storage process are guaranteed, meanwhile, the reagent bag body can rapidly release the reagent into the kit after being cut through the arrangement of the liquid inlet, automatic feeding of the reagent is achieved, and complexity and errors of manual operation are avoided.

Techniques for using combination stain types for machine learning models for digital pathology are described herein. In an example, a system accesses a first image of a sample comprising an immunohistochemistry (IHC) stain for a biomarker. The system accesses a second image of the sample comprising a hematoxylin and eosin (H&E) stain for nuclei. The system can segment tissue regions in the one or more first images and the second image, partitions the tissue regions in the one or more first images and the second image, and extracts features from the set of tiles using a feature extractor. The system can generate, by a machine-learning model, an output classification indicating a first phenotype based on the features extracted from the set of tiles. The machine-learning model can include one or more classifiers and an aggregation model that provides an aggregated output for the set of tiles.

Injectable compositions and methods of preparation, as well as therapeutic uses, of induced pluripotent stem cell (iPSC)-derived notochordal cell (iNC)-loaded microgels are provided. Microfluidic on-chip platform can be utilized to prepare microgels (or microgel particles / spheres) formed from block copolymers that exhibit reverse thermal gelation, so as to encapsulate iNCs. Also provided are preconditioned iNC-loaded microgels and iNCs in bulk hydrogel. Cell purity, identity, viability, sterility, and the stability of microencapsulated iNCs have been evaluated. Safety and efficacy of the compositions as therapeutic candidates has been tested via intradiscal injection in animal models of intervertebral disc (IVD) degeneration and discogenic low back pain. Biobehavioral testing, MRI, and immunohistochemical analyses were utilized to evaluate the regenerative potential and reproducibility of the compositions as therapeutic candidate. Single cell RNA sequencing of the treated IVDs may also reveal mechanism of action of the compositions.

The invention belongs to the technical field of immunohistochemical detection, and discloses a modified composite sealing buffer solution as well as a preparation method and detection application thereof. The modified composite blocking buffer solution comprises a basic buffer system, a composite blocking agent, a nonionic detergent, an endogenous interferent blocking agent and an antibody stabilizer, wherein the basic buffer system provides a stable pH environment and ionic strength; the composite sealing agent firstly occupies a shielding site, and the background is lowered; the nonionic detergent destroys hydrophobic interaction, effectively elute and loosen adsorbed molecules, and promote dissolution of components with relatively strong hydrophobicity; the endogenous interferent blocker can be combined with a receptor firstly, so that non-specific combination of an antibody and the receptor is blocked, and the problem of specific background is solved; the antibody stabilizer can protect the activity of the detection reagent and maintain the stability, and the obtained modified composite sealing buffer solution and the kit thereof have the advantages of multiple cooperative sealing mechanisms, prospective blocking of endogenous interference, improvement of the stability, compatibility and high efficiency of the antibody and the like.

The invention relates to the technical field of medical data processing, and discloses a cancer immunotherapy prognosis prediction method, system and equipment based on CD8 + T cell density in a necrotic area and a medium. The method comprises the following steps: firstly, extracting pathological features on a CD8 immunohistochemical staining (IHC) slice image of tumor tissue of a to-be-detected person after neoadjuvant immunotherapy by using a multi-scale feature extraction model, and then carrying out regional division on the CD8 IHC slice image by using a regional classification model to obtain a necrotic region; then, the CD8 + T cells in the necrotic area are recognized and counted through the target recognition model, the cell density of the CD8 + T cells in the necrotic area is rapidly obtained, and finally, the EFS of the person to be detected is accurately predicted based on the cell density of the CD8 + T cells in the necrotic area. According to the method, efficient and high-precision EFS prediction can be carried out only through the CD8IHC slice image of the tumor tissue, and a doctor can make a proper diagnosis and treatment plan for a patient according to a prediction result.

The application discloses a marker for determining the severity of IgAN kidney tissue lesions and application thereof, and inventors find that ACTN4, ACADS and COL1A1 are significantly differentially expressed proteins in kidney tissues. The significant down-regulation of ACTN4 may cause the change of actin cytoskeleton of IgAN glomerular podocytes; the significant down-regulation of ACAD may indirectly participate in the occurrence process of abnormal structure and function of IgAN renal tubular epithelial cells by affecting fatty acid metabolism in the cells; and the significant up-regulation of COL1A1 may participate in the accumulation of extracellular matrix in the renal interstitium of IgAN, and play a certain role in promoting the renal interstitial fibrosis. The combination of ACTN4, ACADS and COL1A1 has good prediction efficiency for the diagnosis of the severity of IgAN kidney tissue lesions, and the area under the ROC curve is 0.815, P 0.043. In addition, the immunohistochemical results also confirm the expression trend of the three proteins ACTN4, ACADS and COL1A1 in the corresponding kidney tissue substructures in proteomics.

The application describes chromogenic conjugates for color-based detection of targets. The conjugate includes a chromogenic moiety such as rhodamine, rhodol or fluorescein. The chromogenic moiety is linked to a peroxidase substrate. The chromogenic conjugate can be used for immunohistochemical analysis and in situ hybridization. The conjugate can be used to detect 1, 2, 3 or more targets in a sample by color.

The invention discloses application of jellyfish and snow rabbits in inhibition of ERK phosphorylation level and MAPK pathway and an evaluation method of the jellyfish and snow rabbits, and relates to the technical field of biological medicines.The method comprises the following steps that 1, a treated jellyfish and snow rabbits breast cancer cell group and a control breast cancer cell group are established; and step 2, respectively dividing the two groups of samples in the step 1 into two parts, fixing one part in paraformaldehyde with the mass concentration of 10%, treating, embedding in paraffin for immunohistochemical analysis, and quickly freezing the other part for transcriptomics analysis and the like. According to the invention, UPLC-MS is adopted to determine the main components of SMM, the influence of SMM on breast cancer (BC) is evaluated through in-vivo experiments, in order to deeply clarify the mechanism, network pharmacology and transcriptomics analysis are integrated, finally, immunohistochemistry (IHC) is adopted to verify and explore the exact breast cancer resisting mechanism of SMM, and a scientific basis is provided for potential clinical application of SMM.

The invention relates to a confining liquid and method for reducing background signals in immunohistochemical detection, and belongs to the technical field of immunodetection, and the confining liquid comprises whey protein and an anionic surfactant. By utilizing the confining liquid provided by the invention, background signals generated on a glass slide can be reduced or even eliminated, and the convenience and accuracy of interpretation of an immunohistochemical detection result are improved.

A system and method of categorizing protein expression in biological cells may include receiving a Whole Slide Image (WSI) of an Immunohistochemistry (IHC) assay of cells, stained with two or more color-specific markers, of two or more respective proteins, and applying a stain separation algorithm on the WSI image, to obtain two or more single¬ channel marker images. Based on the two or more marker images, embodiments may generate an enhanced color image, representing expression of the two or more proteins in the assay, and prompt a user to assign at least one label to at least one respective location in the enhanced color image. Embodiments may then use the at least one label as supervisory information, to train a machine-learning (ML)-based classification model, to classify at least one cell -representative location according to categories of expression of the at least two proteins.

The invention discloses an enzyme-labeled secondary antibody polymer for immunohistochemical staining. The enzyme-labeled secondary antibody polymer is formed by combining a secondary antibody with a polymer backbone, the polymer is labeled with a marker enzyme, the polymer backbone is polymethacrylate-2-hydroxyethyl ester, and the marker enzyme is connected to polymethacrylate-2-hydroxyethyl ester through a coupling agent. The present invention utilizes polymethacrylate-2-hydroxyethyl ester to modify proteins, reduce immunogenicity and antigenicity, and can also weaken the hydrolysis of proteases and increase the solubility of protein molecules. The enzyme-labeled secondary antibody polymer is applied to immunohistochemical staining and has high specificity and sensitivity.

The application relates to the field of immunohistochemical staining, in particular to a DAB buffer and a DAB staining solution kit for DAB color development. The application discloses a DAB buffer for DAB color development, and the main components are hydrogen peroxide, nonylphenol polyoxyethylene ether, magnesium sulfate and trisodium citrate. The metal ions in the DAB buffer can enhance the electron transfer speed between DAB and hydrogen peroxide, and improve the color development sensitivity. The nonylphenol polyoxyethylene ether can stabilize the hydrogen peroxide, so that the hydrogen peroxide can be stored for a longer time and the cost is saved. The application further discloses a DAB staining solution kit, which comprises a blocking agent, a reaction enhancer, an enzyme-labeled polymer IgG, a DAB concentrated solution, a DAB buffer and hematoxylin, and the above-mentioned DAB buffer for DAB color development. The DAB staining solution kit of the application can improve the detection sensitivity of immunohistochemical staining, and can also improve the storage stability of the DAB color development solution and reduce the cost.

The invention relates to application of a TM4SF1 gene and an inhibitor of the TM4SF1 gene in detection of PVR or preparation of a medicine for treating the PVR, and belongs to the field of biological medicine. PVRMs samples are sequenced, one fibroblast subtype is found to be derived from differentiation of RPE cells through cell subset clustering analysis and quasi-timing analysis, and the TM4SF1 gene participates in regulation and control of the process. The method comprises the following steps: constructing a short interference oligonucleotide capable of silencing a TM4SF1 gene to obtain a TM4SF1 silencing RNA (Ribonucleic Acid); through a Transwell migration experiment, it is found that after the TM4SF1 gene is silenced, fibrosis change caused by TGF-beta 1 can be inhibited; immunohistochemistry and immunocytochemistry show that after the TM4SF1 is silenced, the fibrosis change caused by the TGF-beta 1 can be inhibited through the (TM4SF1-siRNA). The method provided by the invention shows that the TM4SF1 gene expression level can be used as a basis for detecting the proliferative vitretinopathy; the method provided by the invention also shows that the effect of treating proliferative vitretinopathy can be achieved by inhibiting the expression of the TM4SF1 gene.

The invention discloses an antibody or an antigen binding fragment specifically binding to trop2. The antibody or the antigen binding fragment comprises heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3, and light chain complementarity determining regions LCDR1, LCDR2 and LCDR3, the amino acid sequence of the HCDR1 is as shown in SEQ ID NO.1, the amino acid sequence of the HCDR2 is as shown in SEQ ID NO.2, the amino acid sequence of the HCDR3 is as shown in SEQ ID NO.3, the amino acid sequence of the LCDR1 is as shown in SEQ ID NO.4, the amino acid sequence of the LCDR2 is as shown in SEQ ID NO.5, and the amino acid sequence of the LCDR3 is as shown in SEQ ID NO.6. The expression condition of trop2 in human breast cancer and pancreatic cancer cell membrane tissue samples can be detected through an immunohistochemical method, and the adjoint diagnostic kit for the humanized trop2 antibody coupling medicine has the advantages of assisting in precise medication and avoiding invalid treatment.

The invention also related to a device and a computer-implemented method for generating n virtual Immunohistochemical (IHC) stain images from one Hematoxylin and Eosin (H&E) stain image, using the IHC machine learning system obtained thanks to the device for training.

This invention discloses the application of ITPRIPL1 as a biomarker for the diagnosis or prognosis of gastric cancer. Database analysis revealed high expression of ITPRIPL1 in gastric cancer patients. Immunohistochemical staining of samples from clinically diagnosed gastric cancer patients further validated its high expression in gastric cancer tumor cells, with higher ITPRIPL1 expression levels observed in lower-differentiated tumor tissues. This invention provides a novel biomarker for the diagnosis and prognosis of gastric cancer, offering new ideas and directions for immunotherapy of gastric cancer.

The application discloses a marker combination for predicting the curative effect of liposarcoma based on immunohistochemistry, a screening method and a prediction model thereof and a construction method thereof. The application analyzes the tissue phenotype characteristics of a liposarcoma patient by using an immunohistochemistry technology, combines transcriptomic data, screens a suitable marker combination NCF1, CD27, LST1, CD8A and AOAH based on Lasso-logistic regression, and establishes a more accurate immunotherapy curative effect prediction model for the liposarcoma patient.

Described herein are computer-implemented methods for analysis of a tissue sample. An example method includes: annotating the whole tumor regions or set of tumorous sub-regions either on a biomarker image or an H&E image (e.g. from an adjacent serial section of the biomarker image); registering at least a portion of the biomarker image to the H&E image; detecting different cellular and regional tissue structures within the registered H&E image; computing a probability map based on the different detected structures within the registered H&E image; deriving nuclear metrics from each of the biomarker and H&E images; deriving probability metrics from the probability map; and classifying tumor nuclei in the biomarker image based on the computed nuclear and probability metrics.

The present disclosure provides antibodies that specifically bind to protein tyrosine kinase 7 (PTK7), and methods of using such antibodies. In some cases, the PTK7 antibodies are used in an immunohistochemistry (IHC) assay, which can detect the presence of cells expressing PTK7 in a tissue from a patient.

Disclosed herein are methods for identifying a subject as having NSCLC that is predicted or is likely to respond to treatment with an ALK inhibitor, for example crizotinib. The methods include identifying a sample including NSCLC tumor cells as ALK-positive or ALK-negative using immunohistochemistry (IHC) and scoring methods disclosed herein. A subject is identified as having NSCLC likely to respond to treatment with an ALK inhibitor if the sample is identified as ALK-positive and is identified as having NSCLC not likely to respond to treatment with an ALK inhibitor if the sample is identified as ALK-negative. According to certain embodiments of the methods, subjects predicted to respond to an ALK inhibitor may then be treated with an ALK inhibitor such as crizotinib.

The invention belongs to the technical field of biology, and relates to a hybridoma cell strain C8-3-7 and a preparation method thereof. The preservation number of the cell strain C8-3-7 is CCTCC (China Center For Type Culture Collection) No: C202573. The hybridoma cell strain C8-3-7 efficiently expresses the DHX33 antibody and has an infinite proliferation capability. The DHX33 antibody can be specifically combined with DHX33 protein, and can specifically recognize DHX33 protein antigen in ELISA (enzyme-linked immuno sorbent assay) and immunohistochemistry or immunocytochemistry analysis.

The application discloses a BICI scoring system for predicting the curative effect of immunotherapy for metastatic colorectal cancer and application thereof, and belongs to the technical field of biological medicine. The BICI scoring system is based on immunohistochemical detection, integrates four dimensions of angiogenesis, immune checkpoints, TGF-beta signal and immune activation, and is calculated by a formula IHC-BICI=VEGFA+PD-L2+TGFB1x2-CD8 score. Taking 4 points as a cut point, BICI-High and BICI-Low are divided, and a bevacizumab combined with an immune checkpoint inhibitor treatment benefit population is accurately screened. The application also discloses a detection kit containing four specific antibodies, application thereof and a treatment decision method. The scoring system of the application only needs conventional IHC detection, has low cost, excellent prediction effect, is suitable for second-line and above treatment and clinical stratification of MSS / pMMR type metastatic colorectal cancer, and has important clinical application value.

The present disclosure provides antibodies that specifically binds to protein tyrosine kinase 7 (PTK7), as well as methods that employ such antibodies. In some cases, the PTK7 antibodies are used in immunohistochemistry (IHC) assays that can detect the presence of PTK7 expressing cells in tissues from patients.

The application provides an immunohistochemical staining image analysis method, including: cutting a plurality of cell nuclei of an immunohistochemical staining image according to a machine learning model; removing pixels belonging to the cell nuclei in the immunohistochemical staining image and removing pixels meeting a color range to obtain a plurality of cytoplasm pixels; distributing the cytoplasm pixels to the cell nuclei according to the positions of the cytoplasm pixels to form a plurality of cells; and calculating a pixel staining score of each pixel in the cells, thereby calculating a cell staining score of the cells. Thus, the staining score of the cells can be objectively and automatically calculated.

The use of AST-3424 in the preparation of a drug for treating a patient with hepatocellular carcinoma. A pathological paraffin block or pathological section of ex-vivo liver tumor tissue from the patient with hepatocellular carcinoma is subjected to immunohistochemical staining to detect the protein expression level of an AKR1C3 enzyme, with the detection result showing an H-score greater than or equal to 200; or the pathological paraffin block or pathological section of ex-vivo liver tumor tissue from the patient with hepatocellular carcinoma is subjected to immunohistochemical staining to detect the protein expression level of an AKR1C3 enzyme, with the detection result showing that the sum of percentages of moderate-intensity staining and high-intensity staining is greater than or equal to 70%. The dosing regimen for AST-3424 is as follows: in each 21-day cycle, administration is performed on day 1 and day 8; the initial dose is 6.0 mg / m2 per administration; and the patient will be permitted to receive treatment for a maximum of 34 cycles.

The present invention discloses a polymeric nanoenzyme material-coupled antibody and its application in immunohistochemical colorimetric detection, comprising a PAMAM dendrimer and an antibody covalently coupled thereto, wherein the PAMAM dendrimer is modified with a Ru-POD nanozyme on its external branches. The polymeric nanoenzyme material-coupled antibody of the present invention has excellent advantages such as high stability, simple preparation, long service life, and adjustable activity. Compared with the traditional horseradish peroxidase-based polymer enzyme secondary antibody detection system, it improves catalytic performance and storage stability. Its catalytic activity for DAB and H2O2 is comparable to that of natural horseradish peroxidase, and has broad application prospects.

A method for training a machine learning model and a computing system performing same, wherein the machine learning model is trained to analyze biological tissue slide images stained by a immunohistochemical staining method for staining tissues expressing specific biomarkers and thus can be used to further elaborately analyze expression levels of biomarkers, etc., whereby a determination can be made on pathological specimen images by analyzing expression levels of biomarkers, etc. A method and system for training a machine learning model using training data, corresponding to immunohistochemically stained images, generated from multiple feature vectors calculated based on various staining intensity criteria.

Provided are chimeric or recombinant antibodies (Abs), or antigen-binding fragments thereof, or monomeric or dimeric antigen-binding proteins capable of specifically binding to human LAG-3 polypeptides, including human LAG-3 polypeptides expressed on the surface of lymphocytes, such as activated T cells or tumor-infiltrating lymphocytes (TILs), that have infiltrated tumors, and methods for producing and using the same. In an alternative embodiment, the chimeric or recombinant antibodies (Abs), or antigen-binding fragments thereof, or monomeric or dimeric antigen-binding proteins as provided herein are used for in vitro diagnosis, e.g., in immunohistochemistry (IHC), to diagnose and / or treat cancer, e.g., bladder cancer, urothelial carcinoma, breast cancer, lung cancer, non-small cell lung cancer, kidney cancer, renal clear cell carcinoma, and / or melanoma or malignant melanoma, due to their ability to specifically bind to activated T cells or tumor-infiltrating lymphocytes that have infiltrated tumors.